On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
How has patient advocacy grown to become the driver of rare disease drug development? In today's episode of Biorasi's Few & Far Between podcast,...
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
"I love clinical research. I will spend my life in clinical research." Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH Biorasi welcomes...